Abstract
The US Food and Drug Administration (FDA) approves a new prescription drug if its benefits are judged to outweigh its risks in pivotal clinical trials1; the FDA and manufacturers then define the approved indications for the drug based on evidence from the trials. The indication is registered in drug labeling to guide prescribing and promotional statements. It can also help establish the contours of insurance coverage.2 However, pivotal trials leading to FDA approval are necessarily limited in the populations they cover.3 Although attention has been given to limitations in the demographic diversity of the trial population,4,5 less attention has been paid to whether a narrowly defined clinical trial population is then used as the basis for extrapolation of trial findings to a broader population of patients than was represented in those trials. Controversially, the FDA initially approved aducanumab in 2021 for all patients with Alzheimer disease, even though it was studied only in those with mild disease.6

This publication has 20 references indexed in Scilit: